Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many drugs are designed to target tumor-specific antigens, which are molecules ...

In a recent article published in Nature Cancer, a multi-institutional research team led by The University of Osaka describes ...

Scientists have identified a promising new drug target for acute myeloid leukemia, a deadly blood cancer with a five-year ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left without hope.” ...

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...